Allspring Global Investments Holdings LLC increased its position in shares of Chemed Co. (NYSE:CHE – Get Rating) by 1,083.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,136 shares of the company’s stock after acquiring an additional 1,040 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Chemed were worth $495,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Victory Capital Management Inc. grew its stake in shares of Chemed by 594.3% in the 2nd quarter. Victory Capital Management Inc. now owns 198,594 shares of the company’s stock worth $93,218,000 after purchasing an additional 169,989 shares during the last quarter. Invesco Ltd. increased its holdings in shares of Chemed by 144.0% in the first quarter. Invesco Ltd. now owns 184,312 shares of the company’s stock valued at $93,363,000 after buying an additional 108,759 shares in the last quarter. Eagle Asset Management Inc. acquired a new stake in shares of Chemed during the 2nd quarter valued at $44,303,000. Renaissance Technologies LLC boosted its stake in shares of Chemed by 29.2% during the 2nd quarter. Renaissance Technologies LLC now owns 165,995 shares of the company’s stock worth $77,916,000 after acquiring an additional 37,495 shares in the last quarter. Finally, Raymond James & Associates grew its holdings in shares of Chemed by 214.0% in the 3rd quarter. Raymond James & Associates now owns 53,728 shares of the company’s stock worth $23,455,000 after acquiring an additional 36,618 shares during the last quarter. 91.12% of the stock is currently owned by institutional investors.
Insider Buying and Selling at Chemed
In related news, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction on Thursday, November 3rd. The stock was sold at an average price of $482.90, for a total transaction of $965,800.00. Following the completion of the sale, the chief executive officer now directly owns 122,235 shares in the company, valued at $59,027,281.50. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, VP Michael D. Witzeman sold 1,300 shares of the stock in a transaction on Thursday, November 3rd. The shares were sold at an average price of $482.62, for a total transaction of $627,406.00. Following the transaction, the vice president now owns 1,186 shares in the company, valued at approximately $572,387.32. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction on Thursday, November 3rd. The shares were sold at an average price of $482.90, for a total transaction of $965,800.00. Following the completion of the sale, the chief executive officer now directly owns 122,235 shares of the company’s stock, valued at approximately $59,027,281.50. The disclosure for this sale can be found here. Insiders sold 9,036 shares of company stock valued at $4,444,780 in the last quarter. Company insiders own 4.03% of the company’s stock.
Chemed Price Performance
Chemed (NYSE:CHE – Get Rating) last announced its quarterly earnings data on Monday, October 31st. The company reported $4.74 EPS for the quarter, topping analysts’ consensus estimates of $4.61 by $0.13. Chemed had a return on equity of 44.29% and a net margin of 12.31%. The firm had revenue of $526.47 million during the quarter, compared to analyst estimates of $527.05 million. The business’s quarterly revenue was down 2.3% compared to the same quarter last year. During the same period last year, the company posted $5.06 EPS. Equities analysts forecast that Chemed Co. will post 18.69 EPS for the current fiscal year.
Chemed Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Monday, December 5th. Shareholders of record on Monday, November 14th were given a $0.38 dividend. The ex-dividend date was Thursday, November 10th. This represents a $1.52 dividend on an annualized basis and a yield of 0.30%. Chemed’s payout ratio is 8.83%.
Wall Street Analyst Weigh In
A number of research firms recently weighed in on CHE. Royal Bank of Canada increased their price target on Chemed from $541.00 to $545.00 and gave the company an “outperform” rating in a research report on Thursday, November 3rd. StockNews.com downgraded shares of Chemed from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 9th.
Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.
- Get a free copy of the StockNews.com research report on Chemed (CHE)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Analysts Like The Fit Of Skechers USA
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.